References
- Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262–7
- Friedman DS, Wolfs RC, O’Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004;122:532–8
- American Academy of Ophthalmology. Preferred Practice Pattern. Primary Open-Angle Glaucoma. Limited Revision. San Francisco, CA: American Academy of Ophthalmology, 2003
- Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA 1991;17;266:369–74
- Ntim-Amponsah CT, Amoaku WM, Ofosu-Amaah S, et al. Prevalence of glaucoma in an African population. Eye 2004;18:491–7
- Leske MC, Connell AM, Wu SY, et al. Incidence of open-angle glaucoma: the Barbados Eye Studies. The Barbados Eye Studies Group. Arch Ophthalmol 2001;119:89–95
- Quigley HA, West SK, Rodriguez J, et al. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol 2001;119:1819–26
- Varma R, Ying-Lai M, Francis BA, et al. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology 2004;111:1439–48
- Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology 1992;99:1499–504
- Schmier JK, Halpern MT, Jones ML. The economic implications of glaucoma: a literature review. PharmacoEconomics 2007;25:287–308
- Covert D, Robin AL. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Curr Med Res Opin 2006;22:971–6
- Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 2005;112:863–8
- Denis P, Covert D, Realini A. Travoprost in the management of open-angle glaucoma and ocular hypertension. Clin Ophthalmol 2007;1:11–24
- Gold MR, Siegel JE, Russel LB, et al., eds. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996
- Drummond M, Manca A, Sculpher M. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. Int J Technol Assess Health Care 2005;21:165–71
- Goldberg LD, Walt J. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications. PharmacoEconomics 2006;24:251–64
- Fremont AM, Lee PP, Mangione CM, et al. Patterns of care for open-angle glaucoma in managed care. Arch Ophthalmol 2003;121:777–83
- Wolters Kluwer Health Price Rx™ Drug Price and Reference Tool. www.wkhealth.com [Last accessed February 2007]
- Practice Management Information Corporation. Medical Fees in the United States. Los Angeles, CA: Practice Management Information Corporation, 2006
- Fiscella RG, Green A, Patuszynski DH, et al. Medical therapy cost considerations for glaucoma. Am J Ophthalmol 2003;136:18–25
- Platt R, Reardon G, Mozaffari E. Observed time between prescription refills for newer ocular hypotensive agents: the effect of bottle size. Am J Ophthalmol 2004;137(1 Suppl): S17–23
- Fiscella R, Wilensky JT, Chiang TH, et al. Efficiency of instillation methods for prostaglandin medications. J Ocul Pharmacol Ther 2006;22:477–82
- Rouland JF, Berdeaux G, Lafuma A. The economic burden of glaucoma and ocular hypertension: implications for patient management: a review. Drugs Aging 2005;22:315–21
- Schwartz GF, Platt R, Reardon G, et al. Accounting for restart rates in evaluating persistence with ocular hypotensives. Ophthalmology 2007;114:648–52
- Friedman DS, Nordstrom B, Mozaffari E, et al. Glaucoma management among individuals enrolled in a single comprehensive insurance plan. Ophthalmology 2005;112: 1500–4
- Lee PP, Walt JG, Doyle JJ, et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol 2006;124:12–19
- Traverso CE, Walt JG, Kelly SP, et al. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br J Ophthalmol 2005;89: 1245–9
- Kobelt G. Health economics, economic evaluation, and glaucoma. J Glaucoma 2002;11:531–9